Share this to:

Support & Insight for the Autumn of Life

Alzheimer’s Eye Test Aids Prevention Trial

VIDEO + ARTICLE:

The famous “A4 Alzheimer’s Prevention Trial” continues to build momentum. It is adding an Alzheimer’s eye test that can detect signs of Alzheimer’s long before symptoms appear. Learn about Neurovision’s “Retinal Imaging Technology” in the A4 Trial. See how it works.


NeuroVision announced its participation in the landmark Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (or “A4”) clinical trial.

They will be working with investigators at the University of California San Diego School of Medicine (UC San Diego) and the University of Southern California (USC).

The purpose of the A4 study is to test whether a new investigational treatment called “solanezumab” can slow or prevent memory loss caused by Alzheimer’s.

Continued below video…

Beta-amyloid is the main suspect behind Alzheimer’s. Solanezumab works by reducing beta-amyloid accumulation in the brain. That may also slow or prevent memory loss caused by Alzheimer’s disease. Amyloid is a protein normally produced in the brain that can build up in older people, forming amyloid plaque deposits.

The main A4 study is a public-private partnership, funded by the National Institute on Aging at the National Institutes of Health, Eli Lilly and Company, and several philanthropic organizations. USC’s Alzheimer’s Therapeutic Research Institute coordinates the trial, with about 70 study sites in several countries, including the United States, Canada, Australia and Japan.

Scientists believe this buildup of deposits may play a key role in the eventual development of Alzheimer’s disease-related memory loss. The overall goal of the A4 study is to test whether decreasing amyloid accumulation with an antibody investigational treatment can help slow the memory loss associated with Alzheimer’s disease.

“Our best chance of altering the disease may be to start treatment before people have symptoms,” said Dr. Robert Rissman, substudy principal investigator and associate professor of neurosciences at UC San Diego. “Evaluating new approaches such as retinal imaging will allow us to understand how Alzheimer’s neuropathology develops in the eye and how this parallels what is occurring in the brain itself. We are very fortunate to have the opportunity to conduct this substudy in A4 with our USC colleagues.”

Using NeuroVision’s retinal imaging technology, the substudy will characterize retinal amyloid imaging findings in subjects with preclinical AD prior to administration of experimental treatment received as part of the primary A4 study protocol. The substudy will also assess longitudinal changes in retinal amyloid imaging in subjects with preclinical AD and whether it correlates with brain amyloid and cognitive change. One hundred subjects will be recruited into the substudy and imaged annually over three years.

“If successful, this technique could one day be used in the clinic to identify at-risk patients,” said Dr. Michael Rafii, associate professor of neurology at USC and associate professor of neurosciences at UC San Diego. “Dr. Rissman and I recently identified a strong neuropathological signal using NeuroVision’s retinal imaging system in adults with Down Syndrome, a group of individuals who are at increased risk for developing Alzheimer’s disease.”

Steve Verdooner, CEO of NeuroVision, remarked that “this is an exciting opportunity to evaluate our technology in a setting in which it could potentially add significant clinical value. Currently, evaluating amyloid plaque burden in the clinical setting is challenging and has limited scope for scaling up to meet the potential demand for effective new drugs. Our technology is designed to be easy-to-use, reliable and, being noninvasive, have minimal impact on patients. If it works in the way we expect, retinal imaging would streamline enrollment into clinical studies and could help identify candidates for new drugs and monitor their efficacy in a practical and accessible setting.”

MORE INFORMATION:

The A4 study
Please visit A4study.org.

About NeuroVision Imaging LLC

NeuroVision (www.neurovision.com) was formed in 2010 and is headquartered in Sacramento, California. Dr. Keith Black, the company’s chairman and co-founder, is an internationally recognized neurosurgeon, researcher and thought leader in areas of brain and blood-brain barrier function, enhancing the therapeutic effects of treatments in the brain, and optical imaging of the brain. He is the chair of Cedars-Sinai’s Department of Neurosurgery. Steven R. Verdooner, NVI’s CEO as well as a company director, is an experienced medical technology industry veteran who has successfully developed, commercialized and marketed ophthalmological imaging and measurement systems for other diagnostic applications.

SOURCE:

Subscribe
Notify of
guest

0 Comments
Inline Feedbacks
View all comments
B. Berger

B. Berger

Visit Our Pages On:

Welcome

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Related

walking-pasja1000%2Bat%2Bpixabay.jpeg
Is Sitting Bad for the Brain? Maybe Not.
Is keeping seated and sedentary, while intellectually stimulated, part of the best way to care for your brain?
dna, biology, medicine
The Genetic Factor That Fends Off Alzheimer's
A massive study of medical and genetic data shows that people with a particular version of a gene involved in immune...
anti-inflammatory, curcuma longa, curcumin
UCLA: Memory-Mood Boosted by Curcumin Despite Aging
The spice turmeric contains curcumin. In a UCLA study, curcumin significantly improved memory and mildly improved moo...
0
Would love your thoughts, please comment.x
()
x
News, Treatments, Care Tips

Subscribe To The Weekly Newsletter

videos & articles on Research & Prevention
News to Get at the Truth

Subscribe To Our Weekly Newsletter